# Efficacy and Safety of Dorner Tablets and Aspirin for Prevention of Arteriosclerosis Progress in Type 2 Diabetes Mellitus Patients

> **NCT02786979** · PHASE4 · TERMINATED · sponsor: **Astellas Pharma Inc** · enrollment: 190 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Beraprost
- **DRUG:** Aspirin

## Key facts

- **NCT ID:** NCT02786979
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-07
- **Primary completion:** 2013-01
- **Final completion:** 2013-01
- **Target enrollment:** 190 (ACTUAL)
- **Why stopped:** Upon interim analysis, sponsor's decision due to absence of demonstration of efficacy.
- **Last updated:** 2016-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02786979

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02786979, "Efficacy and Safety of Dorner Tablets and Aspirin for Prevention of Arteriosclerosis Progress in Type 2 Diabetes Mellitus Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02786979. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*